Ferumoxytol injection for Anemia (AMAGFeraheme Trial)

Phase 4

Waitlist Available

Led By Stuart Katz, MD

Research Sponsored by NYU Langone Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up month 6

Awards & highlights

This trial is testing a new way to give iron supplements to people who have had a heart device put in, to see if it's better than the old way.

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ month 6

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~month 6

This trial's timeline: 3 weeks for screening, Varies for treatment, and month 6 for reporting.

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage of Patients Who Successfully Complete Ferumoxytol Injection Treatment

1Treatment groups

Experimental Treatment

Group I: Ferumoxytol injection treatmentExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

NYU Langone HealthLead Sponsor

1,379 Previous Clinical Trials

848,117 Total Patients Enrolled

Stuart Katz, MDPrincipal InvestigatorNew York Langone Medical Center

9 Previous Clinical Trials

957 Total Patients Enrolled

~0 spots leftby Jul 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.